Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $183.4 million.

  • SAB Biotherapeutics' Liabilities and Shareholders Equity rose 241.00% to $183.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.9 million, marking a year-over-year increase of 9.19%. This contributed to the annual value of $44.2 million for FY2024, which is 47.35% down from last year.
  • SAB Biotherapeutics' Liabilities and Shareholders Equity amounted to $183.4 million in Q3 2025, which was up 508.87% from $30.1 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Liabilities and Shareholders Equity peaked at $183.4 million during Q3 2025, and registered a low of $28.3 million during Q3 2023.
  • In the last 3 years, SAB Biotherapeutics' Liabilities and Shareholders Equity had a median value of $44.2 million in 2024 and averaged $61.2 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Liabilities and Shareholders Equity crashed by 55.09% in 2022 and then skyrocketed by 241.00% in 2025.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Liabilities and Shareholders Equity stood at $81.1 million in 2021, then plummeted by 37.26% to $50.9 million in 2022, then skyrocketed by 64.90% to $83.9 million in 2023, then tumbled by 47.35% to $44.2 million in 2024, then spiked by 241.00% to $183.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $183.4 million for Q3 2025, versus $30.1 million for Q2 2025 and $38.1 million for Q1 2025.